Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Jun 13, 2014 - 12:25:58 PM



FDA Approves Lymphoseek to Help Determine the Extent of Head and Neck Cancer in the Body

By Staff Editor
Jun 13, 2014 - 12:21:24 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

In 2013, Lymphoseek was approved to help identify lymph nodes closest to a primary tumor in patients with breast cancer or melanoma. Lymph nodes filter lymphatic fluid that flows from the body's tissues. This fluid may contain cancer cells, especially if the fluid drains a part of the body containing a tumor. By surgically removing and examining the lymph nodes that drain a tumor, a procedure called a biopsy, doctors can sometimes determine if a cancer has spread.

With today's approval, Lymphoseek can now be used to guide testing of lymph nodes closest to a primary tumor for cancer, called a "sentinel" lymph node biopsy, in patients with cancer of the head and neck. This new indication will allow for the option of more limited lymph node surgery in patients with sentinel nodes negative for cancer.

"For some patients with head and neck cancer, removal and pathological examination of lymph nodes draining a primary tumor is an important diagnostic evaluation," said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research. "To use Lymphoseek, doctors inject the drug into the tumor area and later, using a handheld radiation detector, find the sentinel lymph nodes that have taken up Lymphoseek's radioactivity."

For this new indication, Lymphoseek's safety and effectiveness were established in a clinical trial of 85 patients with squamous cell carcinoma of the lip, oral cavity, and skin. All patients were injected with Lymphoseek. Surgeons subsequently removed suspected lymph nodes-those identified by Lymphoseek and those based upon tumor location and surgical practice-for pathologic examination. Results showed that Lymphoseek-guided sentinel lymph node biopsy accurately determined if the cancer had spread through the lymphatic system.

The most common side effects identified in clinical trial was pain or irritation at the injection site.

Lymphoseek is marketed by Navidea Biopharmaceuticals, Inc. based in Dublin, Ohio.

For more information:

  • FDA Approved Drugs: Questions and Answers
  • NCI: Head and Neck Cancers
  • ###
  • For advertising/promotion on HealthNewsDigest.com
  • contact Mike McCurdy at 877-634-918o or [email protected] ¬†We have 7,000 journalists as subscribers.


Top of Page

HealthNewsDigest.com

Cancer Issues
Latest Headlines


+ Health Insurance Coverage among Cancer Patients Varies Greatly by Demographics and Cancer Type
+ 'Humanized' Mice Will Lead to Better Testing of Cancer Immunotherapies
+ Dietary Supplements Shown to Increase Cancer Risk
+ New Genomics Tool Could Help Predict Tumor Aggressiveness
+ Yale Launches National Study of Personalized Medicine for Metastatic Melanoma
+ Consider Genetic Counseling for Ovarian Cancer Risk
+ Researchers Sequence Genome of Anaplastic Large Cell Lymphoma, Identify Key Mutations to Target
+ Common Cancers Highjack Powerhouses of Cells
+ Uncovering Genetic Diversity of Pancreatic Cancer
+ Wearable Device Slows Deadly Brain Tumors



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions